Bladder Cancer News
- Pembrolizumab Active in Advanced Urothelial Cancer
- Seagen and Astellas Announce Updated Results from Two Trials of PADCEV® (enfortumab vedotin-ejfv) in Patients with Locally Advanced or Metastatic Urothelial Cancer Not Eligible for Cisplatin Chemotherapy
powered by Surfing Waves
Federal Tax I.D.: EIN 86-0818253